Dementia & Alzheimer's: A Comprehensive Intervention Protocol

A Note on Philosophy. The mainstream medical establishment's current approach to Alzheimer's and dementia is, for most patients, a managed decline. Approved drugs — cholinesterase inhibitors like donepezil, and memantine — offer modest symptomatic benefit for some patients and do nothing to halt or reverse the underlying disease. The two recently approved amyloid-targeting drugs (lecanemab and donanemab) show statistically significant but clinically modest slowing of decline in early-stage patients, carry serious risks including brain swelling and bleeding, and are not available to most people. For late-stage patients, the honest answer from conventional medicine is: we have nothing. This protocol takes a different position. When someone is in late-stage dementia, the risk calculus changes entirely. Interventions that might carry modest risks in a healthy person become worth attempting when the alternative is continued, irreversible decline. The philosophy here is: review everything that could be harming the brain, add everything that might help it, and do so systematically. Some of what follows has strong evidence. Some has preliminary evidence. Some is biologically plausible but unproven in humans. All of it is presented honestly, with its evidence level stated.

PART 1: MEDICATION REVIEW — WHAT MAY BE HARMING THE BRAIN. Before adding anything, review what is already being taken. Several commonly prescribed drug classes have credible evidence of negative cognitive effects, and their removal — done carefully under medical supervision — has in some cases produced meaningful cognitive improvement. This is not anti-medicine. It is precision medicine.

Statins and Cognitive Decline. Statins are among the most prescribed drugs in the world, and their relationship with cognition is genuinely contested. The FDA added a warning about cognitive side effects to all statin labels in 2012, citing reports of memory loss, confusion, and forgetfulness — effects that typically resolved when the drug was stopped. The proposed mechanism is straightforward: the brain is approximately 25% of the body's total cholesterol, and cholesterol is essential for synapse formation, myelin integrity, and neuronal membrane function. Statins cross the blood-brain barrier to varying degrees — lipophilic statins (simvastatin, atorvastatin, lovastatin) cross more readily than hydrophilic ones (pravastatin, rosuvastatin). Several observational studies have found associations between statin use and increased dementia risk, while others have found the opposite or no effect — the literature is genuinely mixed. What is not contested is that some individuals experience significant cognitive improvement when statins are discontinued. For a patient with dementia who is also on a statin, a supervised trial of statin discontinuation — with monitoring of cardiovascular risk — is a reasonable and evidence-informed consideration. This decision must be made with a physician, weighing cardiovascular risk against cognitive benefit.

Anticholinergic Drugs. This is one of the clearest drug-cognition relationships in medicine. Anticholinergic drugs block acetylcholine — the primary neurotransmitter of memory and learning, and the same neurotransmitter that Alzheimer's drugs try to preserve. A 2019 study in JAMA Internal Medicine (Coupland et al.) found that cumulative anticholinergic drug use was associated with a significantly increased risk of dementia, with the association strongest for antidepressants, bladder medications, and antihistamines. Common anticholinergic drugs include: older antihistamines (diphenhydramine — found in Benadryl and many sleep aids), bladder medications (oxybutynin, tolterodine), tricyclic antidepressants (amitriptyline, nortriptyline), certain antipsychotics, and some anti-nausea medications. Any patient with dementia should have their medication list reviewed specifically for anticholinergic burden. The Anticholinergic Cognitive Burden (ACB) scale is a validated tool for this assessment. Reducing or eliminating high-ACB medications — where clinically feasible — is one of the highest-yield, lowest-risk interventions available.

Benzodiazepines and Sleep Medications. Benzodiazepines (diazepam, lorazepam, alprazolam) and Z-drugs (zolpidem, zopiclone) are commonly prescribed in older adults for anxiety and sleep. Both classes impair memory consolidation acutely and have been associated with increased dementia risk in long-term observational studies. A 2014 BMJ study (Billioti de Gage et al.) found a 51% increased risk of dementia in long-term benzodiazepine users. These drugs also increase fall risk significantly. For a patient with dementia, these medications deserve careful review. Tapering should be done slowly and under medical supervision — abrupt discontinuation of benzodiazepines can cause seizures.

Proton Pump Inhibitors (PPIs). PPIs (omeprazole, lansoprazole, pantoprazole) are widely used for acid reflux and are often continued indefinitely without reassessment. Several observational studies have found associations between long-term PPI use and increased dementia risk, with proposed mechanisms including impaired vitamin B12 absorption, reduced magnesium levels, and direct effects on amyloid clearance. A 2016 JAMA Neurology study found regular PPI use was associated with a 44% increased risk of dementia. While causality is not established, long-term PPI use in a dementia patient warrants reassessment — many patients can be managed with H2 blockers or lifestyle modifications instead.

Polypharmacy in General. The average older adult with dementia takes 5–10 medications. Drug-drug interactions, cumulative cognitive burden, and the simple fact that many of these drugs were prescribed for conditions that may have resolved or changed deserve systematic review. A geriatrician or clinical pharmacist conducting a full medication reconciliation — using tools like the Beers Criteria or STOPP/START criteria — can identify medications that are no longer appropriate. This review alone has produced meaningful cognitive improvements in some patients.

PART 2: DIET — THE BRAIN'S MOST POWERFUL DAILY INPUT. What a person eats every day is the single most modifiable factor in brain health. The evidence for dietary intervention in dementia is substantial, and the mechanisms are well understood.

The MIND Diet. The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) was developed specifically for brain health and is the most evidence-supported dietary pattern for dementia prevention and management. A 2015 Rush University study (Morris et al., Alzheimer's & Dementia) found that strict adherence to the MIND diet was associated with a 53% lower rate of Alzheimer's disease, and even moderate adherence with a 35% reduction. The MIND diet emphasises: green leafy vegetables (at least 6 servings per week — kale, spinach, collards, arugula), other vegetables (at least 1 serving per day), berries (at least 2 servings per week — blueberries and strawberries have the strongest evidence), nuts (at least 5 servings per week), olive oil as the primary cooking fat, whole grains (at least 3 servings per day), fish (at least 1 serving per week, preferably fatty fish), beans (at least 4 meals per week), poultry (at least 2 servings per week), and wine in moderation (optional — 1 glass per day). Foods to minimise: red meat, butter and margarine, cheese, pastries and sweets, and fried or fast food.

Ketogenic Diet for Alzheimer's. The brain in Alzheimer's disease has severely impaired glucose metabolism — neurons cannot efficiently use glucose for fuel. This is sometimes called 'Type 3 Diabetes' (a term coined by researcher Suzanne de la Monte). Ketone bodies — produced during fasting or carbohydrate restriction — bypass this glucose metabolism defect and can fuel neurons directly. Multiple small studies have shown cognitive improvements in Alzheimer's patients following ketogenic diets or medium-chain triglyceride (MCT) supplementation. A 2004 study by Henderson et al. found that a single dose of MCT oil improved cognitive performance in Alzheimer's patients within 90 minutes. The Bredesen Protocol (see below) incorporates ketosis as a central element. A practical approach: reduce refined carbohydrates and sugars aggressively, increase healthy fats (olive oil, avocado, coconut oil, fatty fish), and consider adding MCT oil (starting with 1 teaspoon and building to 1–2 tablespoons per day to avoid GI upset). A full ketogenic diet (under 50g carbohydrates per day) may produce stronger effects but requires more careful implementation.

Foods with Specific Brain Evidence. Beyond the overall dietary pattern, specific foods have strong mechanistic and clinical evidence: Blueberries — contain anthocyanins that cross the blood-brain barrier and reduce neuroinflammation; a 2010 University of Cincinnati study found daily blueberry consumption improved memory in older adults with mild cognitive impairment. Fatty fish (salmon, sardines, mackerel, anchovies) — the primary dietary source of DHA, the omega-3 fatty acid that makes up 40% of the brain's polyunsaturated fat. Turmeric/curcumin — inhibits amyloid plaque formation and has anti-neuroinflammatory effects; populations with high turmeric consumption have among the world's lowest rates of Alzheimer's. Extra virgin olive oil — contains oleocanthal, which has been shown to enhance the brain's amyloid clearance mechanisms. Walnuts — the only nut with significant ALA omega-3; associated with better cognitive function in multiple studies. Leafy greens — high in folate, vitamin K, and lutein, all associated with slower cognitive decline. Fermented foods — emerging evidence links gut microbiome health to brain health via the gut-brain axis; kefir, kimchi, sauerkraut, and yogurt support microbiome diversity.

What to Remove from the Diet. Equally important as what to add: refined sugars and high-fructose corn syrup — drive insulin resistance, which impairs brain glucose metabolism and is directly linked to Alzheimer's pathology. Industrial seed oils (canola, soybean, sunflower, corn oil) — high in omega-6 linoleic acid, which promotes neuroinflammation when consumed in excess relative to omega-3. Ultra-processed foods — associated with accelerated cognitive decline in multiple large cohort studies. Alcohol — while moderate red wine consumption is associated with some benefit in observational studies, heavy alcohol use is directly neurotoxic and accelerates brain atrophy. Gluten (for sensitive individuals) — neurological manifestations of gluten sensitivity, including cognitive impairment, are well-documented; a trial of strict gluten elimination is reasonable, particularly if GI symptoms are present.

PART 3: SUPPLEMENTS — THE EVIDENCE HIERARCHY. Supplements are presented here in order of evidence strength. All dosages are general guidelines — individual needs vary and some supplements interact with medications.

Tier 1 — Strong Evidence. Omega-3 DHA/EPA: DHA is the primary structural fat of the brain. Multiple studies show lower DHA levels in Alzheimer's patients. Supplementation with 2–3g per day of combined DHA/EPA (from fish oil or algae oil) is one of the most evidence-supported interventions. Look for triglyceride-form fish oil for better absorption. Vitamin D3: Vitamin D receptors are found throughout the brain, and deficiency is strongly associated with cognitive decline and dementia risk. A 2014 Neurology study found that severe vitamin D deficiency was associated with a 122% increased risk of dementia. Target blood levels of 60–80 ng/mL. Typical supplementation: 5,000–10,000 IU per day with vitamin K2 (MK-7, 100–200mcg) to direct calcium appropriately. Magnesium L-Threonate: The only form of magnesium shown to significantly raise brain magnesium levels. Magnesium is essential for synaptic plasticity and NMDA receptor function. A 2016 MIT study (Slutsky et al.) found magnesium L-threonate reversed cognitive deficits in aged animals. Dose: 1,500–2,000mg per day (providing approximately 140mg elemental magnesium). B Vitamins (B6, B12, Folate): Elevated homocysteine is a well-established risk factor for dementia and brain atrophy. B vitamins lower homocysteine. An Oxford University trial (VITACOG) found that B vitamin supplementation in people with mild cognitive impairment slowed brain atrophy by 53% over two years — but only in those with elevated omega-3 levels, suggesting synergy. Use methylated forms: methylcobalamin (B12), methylfolate (not folic acid), and pyridoxal-5-phosphate (B6). Lion's Mane Mushroom (Hericium erinaceus): Contains hericenones and erinacines that stimulate Nerve Growth Factor (NGF) production — a protein essential for the survival and growth of neurons. A 2009 double-blind RCT (Mori et al., Phytotherapy Research) found significant cognitive improvement in mild cognitive impairment patients taking 3g per day for 16 weeks, with decline returning after stopping. Dose: 500–3,000mg per day of fruiting body extract.

Tier 2 — Promising Evidence. Phosphatidylserine (PS): A phospholipid that makes up a significant portion of neuronal cell membranes. The FDA has approved a qualified health claim for PS and cognitive dysfunction. Multiple RCTs show improvements in memory, concentration, and cognitive performance. Dose: 300mg per day in divided doses. Acetyl-L-Carnitine (ALCAR): Crosses the blood-brain barrier and supports mitochondrial function in neurons. Multiple studies show improvements in memory, attention, and mood in Alzheimer's patients. Dose: 1,500–3,000mg per day. Alpha-Lipoic Acid (ALA): A potent antioxidant that regenerates other antioxidants (vitamins C and E, glutathione) and improves mitochondrial function. Often combined with ALCAR. Dose: 600–1,200mg per day. Coenzyme Q10 (CoQ10/Ubiquinol): Essential for mitochondrial energy production. Brain cells have extremely high energy demands. Use ubiquinol form (the reduced, more bioavailable form) at 200–400mg per day. Particularly important for patients on statins, which deplete CoQ10. Bacopa Monnieri: An Ayurvedic herb with multiple RCTs showing improvements in memory formation and cognitive processing speed. Effects are cumulative — require 8–12 weeks to manifest. Dose: 300–600mg per day of standardised extract (45% bacosides). Ginkgo Biloba: One of the most studied herbs for cognitive function. Improves cerebral blood flow and has antioxidant properties. Evidence is mixed but several studies show modest benefit in Alzheimer's. Dose: 240mg per day of standardised extract (EGb 761). Resveratrol: A polyphenol found in red grapes that activates SIRT1 (a longevity-associated enzyme) and has anti-amyloid properties. A 2015 Georgetown University RCT found resveratrol stabilised a biomarker of Alzheimer's progression. Dose: 500–1,000mg per day with food. NAD+ Precursors (NMN or NR): NAD+ levels decline with age and are critical for DNA repair, mitochondrial function, and neuronal survival. Animal studies show dramatic cognitive improvements with NAD+ restoration. Human data is preliminary but promising. Dose: 500–1,000mg per day of NMN or NR.

Tier 3 — Biologically Plausible, Emerging or Controversial Evidence. Ivermectin: Ivermectin is an antiparasitic drug with a well-established safety profile at standard doses. Its relevance to dementia comes from several directions. First, the parasite hypothesis: some researchers (including Judith Miklossy) have proposed that certain infections — including spirochetes like Borrelia and various parasites — may contribute to Alzheimer's pathology by triggering chronic neuroinflammation and amyloid deposition as an antimicrobial response. Second, ivermectin has demonstrated anti-neuroinflammatory properties in animal models, reducing microglial activation and neuroinflammatory cytokines. Third, a 2021 preprint analysis of large health databases suggested lower rates of dementia in populations with higher ivermectin use. Fourth, ivermectin has shown activity against several viruses and has been proposed to reduce neurological damage from viral infections that may contribute to dementia. The evidence for ivermectin specifically in Alzheimer's is preliminary and largely preclinical. However, given its established safety profile at standard doses (0.2mg/kg body weight), some integrative practitioners include it in comprehensive dementia protocols, particularly where parasitic infection is suspected or where other interventions have failed. This should be done under medical supervision. Fenbendazole: An antiparasitic drug (primarily veterinary) that has gained attention for potential anti-cancer and anti-parasitic properties in humans. The same parasite-dementia hypothesis applies. Evidence is anecdotal and preclinical. Methylene Blue: A century-old compound that has shown remarkable neuroprotective properties in laboratory and animal studies. It improves mitochondrial function, reduces tau aggregation (a hallmark of Alzheimer's), and enhances memory consolidation. A pharmaceutical derivative (LMTM) failed in large clinical trials, but low-dose methylene blue (0.5–4mg per day) is used by some integrative practitioners. It must be pharmaceutical grade (USP), not industrial grade. Interactions with serotonergic drugs are a serious concern. Lithium Orotate: Lithium at prescription doses is a mood stabiliser. At micro-doses (5–10mg of lithium orotate, compared to 300–900mg of lithium carbonate in psychiatry), it has shown neuroprotective effects in multiple studies. A 2011 Brazilian study found that people in regions with higher natural lithium in drinking water had significantly lower rates of Alzheimer's. Lithium inhibits GSK-3β, an enzyme involved in tau phosphorylation. Low-dose lithium orotate is available as a supplement and has a strong safety profile at these doses. Melatonin: Beyond its sleep role, melatonin is a potent antioxidant and has anti-amyloid properties. The brain's melatonin production declines significantly with age and in Alzheimer's. High-dose melatonin (10–20mg at night) is used in some dementia protocols. It also addresses the severe sleep disruption that accompanies dementia. Spermidine: A polyamine found in wheat germ, aged cheese, and mushrooms that induces autophagy — the cellular cleanup process that clears misfolded proteins including amyloid and tau. Emerging evidence from human studies is promising. Dose: 1–10mg per day.

PART 4: PHYSICAL EXERCISE — THE MOST POWERFUL BRAIN INTERVENTION AVAILABLE. Exercise is not optional in a dementia protocol. It is the single most evidence-supported intervention for brain health, with effects that no drug has matched. The mechanisms are well understood: exercise increases BDNF (Brain-Derived Neurotrophic Factor) — often called 'Miracle-Gro for the brain' — which promotes neurogenesis (the growth of new neurons) in the hippocampus, the brain region most affected by Alzheimer's. Exercise also improves cerebral blood flow, reduces neuroinflammation, improves insulin sensitivity, promotes amyloid clearance, and reduces cortisol (which is directly neurotoxic at chronically elevated levels).

Aerobic Exercise. A 2011 University of Pittsburgh study (Erickson et al., PNAS) found that one year of aerobic exercise increased hippocampal volume by 2% in older adults — reversing age-related shrinkage by 1–2 years. Aim for 150 minutes per week of moderate-intensity aerobic exercise. For dementia patients, this means: brisk walking (the most accessible and evidence-supported form), cycling (stationary or outdoor), swimming, dancing (which adds cognitive and social benefits), and chair-based aerobic exercise for those with mobility limitations. Even 10-minute bouts of walking have measurable effects on BDNF. The goal is consistency over intensity. Daily movement, even gentle, is more valuable than occasional intense exercise.

Balance and Coordination Training. The cerebellum — involved in balance and coordination — has extensive connections to the prefrontal cortex and hippocampus. Activities that challenge balance and coordination activate these connections and promote neuroplasticity. Tai chi has the strongest evidence: multiple RCTs show improvements in cognitive function, balance, and quality of life in dementia patients. A 2012 NEJM study found that tai chi significantly improved cognitive performance compared to stretching and resistance training. Other options: yoga, dance, balance board exercises, and simple coordination drills (catching a ball, stepping patterns).

PART 5: COGNITIVE AND MENTAL EXERCISES. The brain responds to challenge with growth — this is neuroplasticity. Cognitive stimulation is not a cure, but it builds 'cognitive reserve' — the brain's resilience to damage — and has been shown to slow functional decline.

Structured Cognitive Stimulation. Cognitive Stimulation Therapy (CST) is the only non-pharmacological intervention recommended by NICE (UK's National Institute for Health and Care Excellence) for dementia. It involves structured group or individual activities that engage thinking, concentration, and memory. Activities include: themed discussions (current events, childhood memories, favourite foods), word games and puzzles, music activities, creative arts, and reminiscence work using photographs and familiar objects. Even for late-stage patients, music from their youth often produces remarkable responses — the neural pathways for music memory are among the last to be affected by Alzheimer's. The SPECAL method (Specialised Early Care for Alzheimer's) and the work of Oliver Sacks on music and memory provide practical frameworks.

Learning New Skills. The most powerful cognitive stimulus is learning something genuinely new — not just repeating familiar activities. Learning a new language, a musical instrument, a craft, or a new physical skill forces the brain to form new neural connections. For dementia patients, the goal is not mastery but engagement. Even attempting to learn something new — with patience and repetition — activates neuroplasticity mechanisms. Digital tools like Duolingo (language), Simply Piano (music), and BrainHQ (evidence-based cognitive training) can be adapted for varying ability levels.

Social Engagement. Social isolation is one of the strongest risk factors for dementia progression. Human social interaction is cognitively demanding — it requires reading facial expressions, following conversation, managing emotional responses, and retrieving memories. Regular social engagement — family visits, community groups, day centres, video calls — should be treated as a medical intervention, not a luxury. The quality of social interaction matters: genuine conversation and shared activities are more beneficial than passive co-presence.

PART 6: SLEEP — THE BRAIN'S CLEANING CYCLE. Sleep is when the brain clears amyloid and tau through the glymphatic system — a waste-clearance network that is 10 times more active during sleep than waking. Chronic sleep deprivation accelerates amyloid accumulation. This is not peripheral — it is central to Alzheimer's pathology. Optimising sleep in dementia patients is one of the highest-priority interventions. Strategies: maintain consistent sleep and wake times (even on weekends), maximise morning light exposure (10–30 minutes of bright outdoor light within an hour of waking sets the circadian clock), minimise blue light exposure after sunset, keep the bedroom cool (65–68°F / 18–20°C), address sleep apnoea aggressively (untreated sleep apnoea dramatically accelerates cognitive decline — CPAP therapy has shown cognitive benefits in dementia patients), use melatonin (0.5–20mg, 30–60 minutes before bed), and consider magnesium glycinate (400mg at night) for sleep quality. Avoid sedative sleep medications (see Part 1).

PART 7: STRESS REDUCTION AND EMOTIONAL WELLBEING. Chronic psychological stress elevates cortisol, which is directly neurotoxic — it kills hippocampal neurons and impairs memory consolidation. Stress management is not soft medicine. Mindfulness-Based Stress Reduction (MBSR) has been shown to reduce cortisol, increase grey matter density in the prefrontal cortex, and improve cognitive function in older adults. For dementia patients who can engage with it, even simplified mindfulness practices (5–10 minutes of guided breathing, body scan, or gentle meditation) have measurable benefits. For those who cannot, the caregiver's stress level directly affects the patient — caregiver wellbeing is part of the treatment protocol. Other evidence-supported stress reduction approaches: time in nature (forest bathing reduces cortisol and inflammatory markers), pet therapy, music therapy, and gentle massage.

PART 8: THE BREDESEN PROTOCOL (ReCODE). Dr. Dale Bredesen, a UCLA neurologist, developed the ReCODE (Reversal of Cognitive Decline) protocol — a comprehensive, personalised approach that addresses multiple simultaneous drivers of Alzheimer's. His 2014 paper in Aging reported the first documented cases of cognitive reversal in Alzheimer's patients using a multi-modal protocol. The ReCODE protocol identifies and addresses: metabolic factors (insulin resistance, inflammation, nutrient deficiencies), toxic exposures (heavy metals, mycotoxins from mould, organic toxins), infectious contributors (Herpes simplex, Lyme disease, P. gingivalis from gum disease), hormonal imbalances (thyroid, sex hormones, cortisol), and structural factors (sleep apnoea, vascular disease). The protocol is personalised based on extensive laboratory testing and is not a one-size-fits-all approach. Bredesen's published case series show remarkable results — patients reversing from MCI and early Alzheimer's to normal cognitive function. Critics note the lack of large RCTs. Proponents note that the multi-modal nature of the protocol makes RCT design difficult, and that the results in individual patients are clinically meaningful regardless. For late-stage patients, the full ReCODE protocol may not be feasible, but its core principles — addressing metabolic health, removing toxins, optimising nutrition and sleep, and targeted supplementation — are applicable at any stage.

PART 9: ADDRESSING POTENTIAL INFECTIOUS AND TOXIC CONTRIBUTORS. Emerging research suggests that Alzheimer's may not be a single disease but a syndrome with multiple potential triggers, including infectious agents and environmental toxins. Oral Health and P. gingivalis: A 2019 Science Advances study found the bacterium Porphyromonas gingivalis — the primary pathogen in gum disease — in the brains of Alzheimer's patients, along with its toxic enzymes (gingipains). Aggressive dental hygiene — twice-daily brushing, daily flossing, oil pulling with coconut oil, and regular professional cleaning — is a legitimate dementia intervention. Herpes Simplex Virus (HSV-1): Multiple studies have found HSV-1 DNA in the brains of Alzheimer's patients, concentrated in amyloid plaques. The virus may trigger amyloid production as an antimicrobial defence. Antiviral treatment (acyclovir, valacyclovir) has been proposed as a dementia intervention. A 2018 Taiwan study found that people treated with antiviral drugs for herpes infections had a dramatically lower rate of dementia. Heavy Metal Toxicity: Aluminium, mercury, and lead have all been found in elevated concentrations in Alzheimer's brains. Sources include dental amalgams, aluminium cookware, certain vaccines, and environmental exposure. Testing (hair mineral analysis, urine toxic metals) and targeted chelation or binding (chlorella, cilantro, modified citrus pectin, DMSA under medical supervision) may be relevant for some patients. Mould and Mycotoxins: Dr. Bredesen identifies mycotoxin exposure (from water-damaged buildings) as a significant contributor to a subset of Alzheimer's cases. If the patient has lived or worked in a water-damaged building, mycotoxin testing (urine mycotoxins) and remediation of the exposure source is warranted.

PART 10: LATE-STAGE SPECIFIC CONSIDERATIONS. For patients in late-stage dementia, the focus shifts from reversal to quality of life, comfort, and slowing further decline. Several interventions are particularly relevant at this stage. Sensory stimulation: Touch, music, familiar scents, and visual stimulation can reach patients who can no longer communicate verbally. Music from the patient's youth is particularly powerful — the emotional memory system (amygdala) is relatively preserved even in late-stage Alzheimer's. The documentary 'Alive Inside' documents remarkable responses to personalised music playlists. Bright light therapy: A 2019 MIT study found that 40Hz flickering light (gamma frequency) reduced amyloid and tau in mouse models of Alzheimer's. Human trials are underway. Devices delivering 40Hz light and sound stimulation (such as the Cognito Therapeutics device) are in clinical trials. Some practitioners use standard bright light therapy (10,000 lux for 30 minutes in the morning) for circadian rhythm stabilisation and mood. Hyperbaric Oxygen Therapy (HBOT): A 2020 Israeli study (Shapira et al.) found that HBOT significantly improved cognitive function and cerebral blood flow in Alzheimer's patients. The proposed mechanism is improved oxygen delivery to hypoperfused brain regions and stimulation of neuroplasticity. HBOT is available at specialist clinics and some hospitals. Transcranial Magnetic Stimulation (TMS) and Transcranial Direct Current Stimulation (tDCS): Non-invasive brain stimulation techniques that modulate neuronal activity. Multiple small studies show cognitive improvements in Alzheimer's patients. NeuroAD (a combined TMS/cognitive training system) is approved in some countries for Alzheimer's treatment. Dignity and purpose: For late-stage patients, maintaining a sense of identity, dignity, and purpose is not separate from medical treatment — it is medical treatment. Validation therapy, person-centred care, and maintaining connection to the patient's life history and values are associated with better outcomes and quality of life.

PART 11: A PRACTICAL DAILY PROTOCOL. Morning: 10–30 minutes of outdoor light exposure within 1 hour of waking. 20–30 minutes of aerobic exercise (walk, cycle, swim). Breakfast emphasising brain foods: eggs, blueberries, walnuts, leafy greens, olive oil. Morning supplements: omega-3 DHA/EPA (2–3g), vitamin D3 (5,000 IU) with K2, magnesium L-threonate (500mg), lion's mane mushroom (1,000mg), B-complex (methylated), phosphatidylserine (100mg). MCT oil (1–2 tablespoons) in coffee or smoothie. Midday: Cognitive stimulation activity (30–60 minutes): music, conversation, puzzle, learning activity. Lunch: MIND diet meal — salad with olive oil, fish or legumes, vegetables. Afternoon: Social engagement or meaningful activity. Balance/coordination exercise (tai chi, yoga, dance) 2–3 times per week. Resistance training 2 times per week. Afternoon supplements: acetyl-L-carnitine (500mg), alpha-lipoic acid (300mg), CoQ10/ubiquinol (200mg), bacopa monnieri (300mg). Evening: Dinner: Mediterranean-style, low in refined carbohydrates. Stress reduction practice: guided breathing, gentle music, nature time. Minimise blue light after sunset. Evening supplements: magnesium glycinate (400mg), melatonin (0.5–10mg), resveratrol (500mg). Consistent bedtime. Weekly: Review medication list with prescriber. Dental hygiene appointment monthly. Blood work every 3–6 months: vitamin D, B12, homocysteine, omega-3 index, fasting insulin, HbA1c, thyroid panel, inflammatory markers (CRP, IL-6).